Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial

Immunovant Inc. (NASDAQ:IMVT) is one of the 10 Stocks With Insane Returns Right Now.

Immunovant saw its share prices soar to a new five-year high on Wednesday, as investors took heart from the stellar results of its clinical trial to study its drug candidate for hard-to-treat rheumatoid arthritis.

In an updated report, Immunovant Inc. (NASDAQ:IMVT) said that its treatment candidate, IMVT-1402, showed clinically meaningful response rates of 72.7 percent ACR20, 54.5 percent ACR50, and 35.8 percent ACR70 at Week 16.

Photo by George Morina on Pexels

Immunovant Inc. (NASDAQ:IMVT) said that it would announce further updates on the program in the second half of 2026.

Following the results, the company’s shares climbed to their highest price of $36.28 before paring gains to end the session just up by 35.26 percent at $35.56 apiece.

In other news, investment firm Stifel reiterated its “buy” recommendation and $49 price target for Immunovant Inc. (NASDAQ:IMVT), reflecting its confidence that the results would soon progress to the regulatory approval stage and commercial launch.

The biopharmaceutical company also reported its earnings performance in the first quarter of the year, with net losses widening by 38.9 percent to $147.8 million from $106.4 million in the same period last year.

While we acknowledge the risk and potential of IMVT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IMVT and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1